Regeneron Pharmaceuticals, Inc. (REGN) Tops Q4 EPS by 36c

February 14, 2013 6:36 AM EST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q4 EPS of $1.47, $0.36 better than the analyst estimate of $1.11. Revenue for the quarter came in at $415 million versus the consensus estimate of $392.64 million.

For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings